Prof Scott Williams
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
75 Scholarly works
4 Projects
HIGHLIGHTS
2026
Journal article
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
DOI: 10.1016/S1470-2045(26)00017-32026
Journal article
Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer.
DOI: 10.1158/1078-0432.CCR-25-40012025
Journal article
LBA86 Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)
DOI: 10.1016/j.annonc.2025.09.1022025
Journal article
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
DOI: 10.1038/s41591-025-03704-92025
Journal article
Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177 Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).
DOI: 10.1200/jco.2025.43.16_suppl.50202019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2017
Research Grant
Biofocussed Prostate Cancer Radiotherapy (Birt): A Personalised Approach to Delivering the Right Dose to the Right Place
RECENT SCHOLARLY WORKS
2025
Journal article
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials
DOI: 10.1016/j.eururo.2024.04.0382024
Journal article
Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer
DOI: 10.1038/s41585-024-00913-82024
Journal article
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer
DOI: 10.1016/j.annonc.2023.11.0172024
Journal article
Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study
DOI: 10.1016/j.eururo.2023.08.0262024
Journal article
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
DOI: 10.1016/S1470-2045(23)00529-6
RECENT PROJECTS
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Strategies for Psma-Negative Disease
2019
Internal Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease